Clonidine hydrochloride extended release test tablets (Batch no.
Stock solutions of clonidine hydrochloride were prepared in HPLC mobile phase at concentrations of 1 mg/ml and were stored at 4[degrees]C.
Fully-integrated pharmaceutical company APP Pharmaceuticals Inc has received approval from the US Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths, the company announced today.
Clonidine Hydrochloride Injection is reportedly therapeutically equivalent to the reference-listed drug Duraclon, currently marketed by Astellas US Holding Inc.
Reddy's Delayed-ReleaseTablets, 500 mg/20 mg (base), 375 mg (20 mg (base) Paricalcitol Capsules, 1 mcg, 2 mcg, 4 mcg Teva Clonidine Hydrochloride
Extended-Release Anchen Tablets, 0.
Torch EM: Remission of facial and scalp hyperhidrosis with clonidine hydrochloride
and topical aluminum chloride.
The approval of APP's Clonidine Hydrochloride
further strengthens the company's analgesic portfolio of products and helps solidify our continued leadership as a leading generic injectable company," said John Ducker, President and Chief Executive Officer of APP Pharmaceuticals.
375% Bupivacaine with Clonidine hydrochloride
100[micro]g (1ml of 150[micro]g diluted with 2ml 0.
Kapvay is said to be the only formulation of clonidine hydrochloride
approved by the agency for the treatment of ADHD and is the first FDA-approved ADHD treatment indicated for use as add-on therapy to stimulant medication.
The current study of 200 children with ADHD is the second Phase III trial in a year to investigate the safety and efficacy of Clonicel, a long-acting version of clonidine hydrochloride
CloniBID is a 12-hour, sustained-release formulation of clonidine hydrochloride
CloniBID and Clonicel are both 12-hour, sustained-release formulations of clonidine hydrochloride
In July 2007, Sciele signed an exclusive licensing agreement with Addrenex to market a sustained-release formulation of clonidine hydrochloride
for the treatment of ADHD and hypertension.
Food & Drug Administration (FDA), CLONICEL[R], a patented, sustained-release formulation of clonidine hydrochloride
for the treatment of hypertension and attention deficit and hyperactivity disorder in North America.
The Bertek sales force will add Zagam(R) to its current product portfolio which includes Maxzide(R), a once-a-day triamterene hydrochlorothiazide diuretic, Nitrek(R), a nitroglycerin transdermal patch system, and Clorpres(TM), a combination of clonidine hydrochloride